Tool Downloads

BOTOX^® Cosmetic and JUVÉDERM^® are pleased to offer the Treatment Visualizer for use on the web sites of physicians.
These tools will educate your patients about a BOTOX^® Cosmetic or JUVÉDERM^® treatment, but do not replace a
consultation by a physician. When you download these tools and add to your website, an additional page will be created
featuring the tool. To ensure customer use, we recommend creating a link on your home page to one or both tools.
Should you encounter any technical issues related to installing or operating these tools, contact the professional
responsible for maintenance and/or programming of your website.

Please note that altering the downloadable files in any way is not permissable, and that Allergan is not responsible for any technical
issues related to installing or operating the tools. Allergan reserves the right to prevent the use of these tools at any time and
without notice.

These tools are not a substitute for a consultation with a qualified healthcare professional. When you decide on and consult with a
qualified healthcare professional, he/she will detemine the severity of your wrinkles and folds and whether BOTOX^® Cosmetic or
JUVÉDERM^® is right for you. He/she may recommend a different treatment based on your individual needs to help you achive your
desired result. Allergan, www.BOTOXCosmetic.com and www.juvederm.com are not engaged in providing medical advice or
services, and do not endorse or warrant any specific technique, method or treatment, or outcome. It is up to your individual healthcare professional to use his/her best medical judgment when making recommendations and determining appropriate patient care.

BOTOX^® Cosmetic is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in patients 18 to 65 years of age.

IMPORTANT SAFETY INFORMATION

Distant Spread of Toxin Effect
Postmarketing reports indicate that the effects of BOTOX® Cosmetic and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have underlying conditions that would predispose them to these symptoms. In unapproved uses, including spasticity in children and adults, and in approved indications, cases of spread of effect have occurred at doses comparable to those used to treat cervical dystonia and at lower doses.

CONTRAINDICATIONS
BOTOX® Cosmetic is contraindicated in the presence of infection at the proposed injection site(s) and in individuals with known hypersensitivity to any botulinum toxin preparation or to any of the components in the formulation.

WARNINGS
The recommended dosage and frequency of administration for BOTOX® Cosmetic should not be exceeded. Risks resulting from administration at higher dosages are not known.

Lack of Interchangeability between Botulinum Toxin Products
The potency Units of BOTOX® Cosmetic are specific to the preparation and assay method utilized. They are not interchangeable with other preparations of botulinum toxin products and, therefore, units of biological activity of BOTOX® Cosmetic cannot be compared to or converted into units of any other botulinum toxin products assessed with any other specific assay method.

Spread of Toxin Effect
Postmarketing safety data from BOTOX® Cosmetic and other approved botulinum toxins suggest that botulinum toxin effects may, in some cases, be observed beyond the site of local injection. The symptoms are consistent with the mechanism of action of botulinum toxin and may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death related to spread of toxin effects. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults treated for spasticity and other conditions, and particularly in those patients who have underlying conditions that would predispose them to these symptoms. In unapproved uses, including spasticity in children and adults, and in approved indications, symptoms consistent with spread of toxin effect have been reported at doses comparable to or lower than doses used to treat cervical dystonia.

No definitive serious adverse event reports of distant spread of toxin effect associated with dermatologic use of BOTOX® Cosmetic at the labeled dose of 20 Units (for glabellar lines) have been reported.

Hypersensitivity Reactions
Serious and/or immediate hypersensitivity reactions have been reported. These reactions include anaphylaxis, urticaria, soft tissue edema, and dyspnea.

Pre-Existing Neuromuscular DisordersIndividuals with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junctional disorders (e.g., myasthenia gravis or Lambert-Eaton syndrome) should be monitored particularly closely when given botulinum toxin. Patients with neuromuscular disorders may be at increased risk of clinically significant effects including severe dysphagia and respiratory compromise from typical doses of BOTOX® Cosmetic.

ADVERSE REACTIONS

General
The most serious adverse events reported after treatment with botulinum toxin include spontaneous reports of death, sometimes associated with anaphylaxis, dysphagia, pneumonia, and/or other significant debility.

There have also been reports of adverse events involving the cardiovascular system, including arrhythmia and myocardial infarction, some with fatal outcomes. Some of these patients had risk factors including pre-existing cardiovascular disease.

The most frequently reported adverse events following injection of BOTOX® Cosmetic include blepharoptosis and nausea.

Overdosage
Excessive doses of BOTOX® Cosmetic may be expected to produce neuromuscular weakness with a variety of symptoms. Respiratory support may be required where excessive doses cause paralysis of respiratory muscles. In the event of overdose, the patient should be medically monitored for symptoms of excessive muscle weakness or muscle paralysis.

In the event of suspected or actual overdosage, please contact your local or state Health Department to process a request for antitoxin through the CDC. If you do not receive a response within 30 minutes, please contact the CDC directly at 1-770-488-7100.

Please see BOTOX® Cosmetic Full Prescribing Information and Medication Guide.

A brief Description of Relevant Indications for Use, Contraindications, Warnings, Precautions, and Adverse Events for
JUVÉDERM^® Injectable Gel

Indication:In the United States,JUVÉDERM^® injectable gel is indicated for correction of moderate to severe facial wrinkles and
folds (such as nasolabial folds).

Contradictions: JUVÉDERM^® injectable gel should not be used in patients who have severe allergies marked by a history of
anaphylaxis or history or presence of multiple severe allergies. JUVÉDERM^® injectable gel should not be used in patients with a
history of allergies to Gram-positive bacterial proteins.

Warnings: JUVÉDERM^® injectable gel should not be injected into blood vessels. If there is an active inflammatory process or
infection at specific injection sites, treatment should be deferred until the underlying process is controlled.

Precautions: The safety of JUVÉDERM^® injectable gel for use during pregnancy, in breastfeeding females, or in patients under
18 years has not been established. The safety and effectiveness of JUVÉDERM^® injectable gel for the treatment of areas other
than facial wrinkles and folds (such as lips) have been established in controlled clinical studies. Patients who are using substances
that can prolong bleeding, such as aspirin or ibuprofen, as with any injection, may experience increased bruising or bleeding at
injection site. Patients should inform their physician before treatment if they are using these types of substances. As with all
skin-injection procedures, there is a risk of infection. JUVÉDERM^® injectable gel should be used with caution in patients on
immunosuppressive therapy, or therapy used to decrease the body's immune reponse, as there may be an increased risk of
infection. The safety of JUVÉDERM^® injectable gel in patients with a history of excessive scarring (eg, hypertrophic scarring and
keloid formations) and pigmentation disorders has not been studied. If laser treatment, chemical peel, or any other procedure
based on active dermal response is considered after treatment with JUVÉDERM^® injectable gel, or if JUVÉDERM^® injectable gel
is administered before the skin has healed completely after such a procedure, there is a possible risk of an inflamatory reaction
at the treatment site.

Adverse events: The most commonly reported side effects are temporary injection-site redness, swelling, pain/tenderness,
firmness, lumps/bumps, and bruising. Most side effects are mild or moderate in nature, and their duration is short lasting (7 days or
less).

Important: For full safety information, please visit www.juvederm.com or call Allergan Product Support at 1-877-345-5372.

CAUTION: This device is restricted to sale by or on the other of a physician.